We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Masimo Gets CE Mark for RRp on MightySat Rx Pulse Oximeter
Read MoreHide Full Article
Irvine, CA-based Masimo Corporation (MASI - Free Report) recently announced the receipt of CE mark approval for respiration rate measurement (RRp) on MightySat Rx fingertip pulse oximeter. Notably, Masimo’s flagship MightySat Rx is a non-invasive device that measures oxygen saturation, pulse rate, perfusion index and pleth variability index.
With the assimilation of RRp facility, MightySat Rx can now have an account of the respiration rate of the patients using the same fingertip sensor that measures the above attributes. However, RRp does not have 510(k) clearance and is not available in the U.S.
MightySat Rx is the smallest, most compact pulse oximeter that provides a bluetooth wireless interface to the company’s flagship Masimo Professional Health mobile application.
Per management, the addition of RRp facility to this platform would fortify the company’s position in the field of mobile monitoring devices for the professional caregiver market.
Stock Performance
Over the last three months, the price performance of Masimo has been encouraging. The stock added 29.7%, higher than the Zacks classified Medical – Instruments sub-industry’s gain of 4.5%.
Also, the current level compares favorably with the S&P 500’s return of 6.5% over the same time frame. Added to this, a long-term expected earnings growth rate of 15% instills confidence in investors.
This positive price trend signifies the company’s Zacks Rank #2 (Buy) and raises hopes of outperformance in the near term.
Bottom Line
We believe that the latest development will strengthen the company’s product portfolio, helping it to tap in on the abundant opportunities in Europe. Even the global market trends seem to be quite lucrative, as an analysis by the Global Industry Analysts reveals that the Pulse Oximeters market is projected to reach a worth of $2.3 billion by 2020.
Masimo’s other non-invasive products like SET pulse oximeter and rainbow SET technology have been key growth catalysts. New product launches and growing installed base of its existing devices are going to help Masimo gain greater market traction.
Other Stocks to Consider
Other favorably ranked stocks in the broader medical sector include Glaukos Corporation (GKOS - Free Report) , Avinger, Inc. (AVGR - Free Report) and Fluidigm Corporation . Notably, Glaukos sports a Zacks Rank #1 (Strong Buy) while Avinger and Fluidigm carry a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Glaukos Corporation has a long-term expected earnings growth rate of approximately 25%. Notably, the stock represents an impressive one-year return of 180.8%.
Avinger projects sales growth of 30.7% for the current year. Additionally, the company posted a positive earnings surprise of 27% in the last quarter.
Fluidigm Corporation has a long-term expected earnings growth rate of 25%. The stock has added 12.1% over the last three months.
Just Released – Driverless Cars: Your Roadmap to Mega-Profits Today
In this latest Special Report, Zacks’ Aggressive Growth Strategist Brian Bolan explores a full-blown technological breakthrough in the making – autonomous cars. He also spotlights 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Masimo Gets CE Mark for RRp on MightySat Rx Pulse Oximeter
Irvine, CA-based Masimo Corporation (MASI - Free Report) recently announced the receipt of CE mark approval for respiration rate measurement (RRp) on MightySat Rx fingertip pulse oximeter. Notably, Masimo’s flagship MightySat Rx is a non-invasive device that measures oxygen saturation, pulse rate, perfusion index and pleth variability index.
With the assimilation of RRp facility, MightySat Rx can now have an account of the respiration rate of the patients using the same fingertip sensor that measures the above attributes. However, RRp does not have 510(k) clearance and is not available in the U.S.
MightySat Rx is the smallest, most compact pulse oximeter that provides a bluetooth wireless interface to the company’s flagship Masimo Professional Health mobile application.
Per management, the addition of RRp facility to this platform would fortify the company’s position in the field of mobile monitoring devices for the professional caregiver market.
Stock Performance
Over the last three months, the price performance of Masimo has been encouraging. The stock added 29.7%, higher than the Zacks classified Medical – Instruments sub-industry’s gain of 4.5%.
Also, the current level compares favorably with the S&P 500’s return of 6.5% over the same time frame. Added to this, a long-term expected earnings growth rate of 15% instills confidence in investors.
This positive price trend signifies the company’s Zacks Rank #2 (Buy) and raises hopes of outperformance in the near term.
Bottom Line
We believe that the latest development will strengthen the company’s product portfolio, helping it to tap in on the abundant opportunities in Europe. Even the global market trends seem to be quite lucrative, as an analysis by the Global Industry Analysts reveals that the Pulse Oximeters market is projected to reach a worth of $2.3 billion by 2020.
Express Scripts Holding Company Price
Express Scripts Holding Company Price | Express Scripts Holding Company Quote
Masimo’s other non-invasive products like SET pulse oximeter and rainbow SET technology have been key growth catalysts. New product launches and growing installed base of its existing devices are going to help Masimo gain greater market traction.
Other Stocks to Consider
Other favorably ranked stocks in the broader medical sector include Glaukos Corporation (GKOS - Free Report) , Avinger, Inc. (AVGR - Free Report) and Fluidigm Corporation . Notably, Glaukos sports a Zacks Rank #1 (Strong Buy) while Avinger and Fluidigm carry a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Glaukos Corporation has a long-term expected earnings growth rate of approximately 25%. Notably, the stock represents an impressive one-year return of 180.8%.
Avinger projects sales growth of 30.7% for the current year. Additionally, the company posted a positive earnings surprise of 27% in the last quarter.
Fluidigm Corporation has a long-term expected earnings growth rate of 25%. The stock has added 12.1% over the last three months.
Just Released – Driverless Cars: Your Roadmap to Mega-Profits Today
In this latest Special Report, Zacks’ Aggressive Growth Strategist Brian Bolan explores a full-blown technological breakthrough in the making – autonomous cars. He also spotlights 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>